Inflammatory Disease, Autoimmune Diseases
Conditions
Keywords
Personalized treatment, Inflammatory diseases, auto-inflammatory diseases, auto-immune diseases, Targeted treatments, skin
Brief summary
Inflammatory diseases may display atypical features making such patients impossible to classify. Management of these cases in daily practice cannot rely on the results of clinical trials nor on guidelines. DNA and RNA mapping have become major tools to understand and sometimes direct the treatment strategy in oncology. This study aims to test whether a precise analysis of molecular pathways in inflammatory, non classified diseases, can constitute a predictive tool of therapeutic efficiency
Detailed description
This is a phase IIb study. The main objective of this study is to evaluate the efficacy of targeted treatments in patients displaying a non-classified, severe and resistant inflammatory disease. Targeted treatments for each patient will have been selected through an algorithm based on molecular analysis of specific altered inflammatory signaling pathway. Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®, Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using molecular analysis and decision making procedure by the Scientific committee. For each patient, one targeted treatment will be administered according to the SmPC procedure for a treatment period of 6 months. Primary efficacy endpoint: Response will be assessed at month 6 with a composite endpoint defined as improvement of at least 2 of the 3 following parameters: * 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10 mm), * and/or 50% improvement of cutaneous activity assessed by the involved skin surface area, * and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin). An independent adjudication committee blinded to the treatment received, will review primary endpoint for all patients based on clinical files and standardized photographs, to validate the response. Other secondary criteria will be assessed. Overall, this study will require a molecular analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance of targeted treatments chosen in a personalized analysis when classification is impossible.
Interventions
DRUGKineret
100 mg, once/day sc 6 months
DRUGHumira
40 mg/15 days sc 6 months
DRUGStelara
45 mg/12 weeks sc, 6 months
DRUGCosentyx
300mg sc every week for 1 month, then 300 mg/month sc for 5 months
DRUGRoactemra
480 mg/perf/4 weeks 6 months
DRUGRituximab
2 sessions of 1000 mg at inclusion and 15 days after inclusion
Sponsors
URC-CIC Paris Descartes Necker Cochin
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients (men or women) aged 18 years old and over * Patients presenting inflammatory non classified disease targeting at least 2 organs involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract, eye, nerves and brain tissues, respiratory tract, cardio-vascular disorders, genito-urinary tract including kidney, musculo-skeletal tissues. Skin involvement is mandatory in order to be able to compare involved and non-involved tissue * Signed informed consent The disease should be considered as non-classified despite classical and adapted investigations and evaluation through expert committee meeting. The disease alters significantly quality of life. The impairment of quality of life will be assessed based on the investigator's assessment. The disease has been resistant to at least two prior lines of treatment \[for example : Hydroxychloroquine, Chloroquine, Colchicine, Methotrexate, Ciclosporine, Azathioprine, Mycophenolate mofetil, Disulone, Corticosteroids (prednisone, prednisolone, dexamethasone, methylprednisolone…)\].
Exclusion criteria
* Patients presenting disease which is not featured by lesional and healthy skin areas, easy to biopsy * Patients refusing biopsies * Pregnancy * Women of child-bearing potential unable to receive highly efficient contraception such as combined oral contraceptives, intra-uterine disposals, hormonal implants or the use of male condoms recommended in case of unstable or irregular partner or as a replacement method for transient unacessebility to hormonal method * Breastfeeding * Patients presenting disease needing urgent therapeutic measures * Patients without health insurance or social security * Participation in another interventional trial * Patients under legal protection * Patients unable to respect the wash out delay of previously taken medications before biopsy and before treatment initiation : * Hydroxychloroquine (wash out period = 30 days) * Chloroquine (wash out period = 7 days) * Colchicine (wash out period = 7 days) * Methotrexate (wash out period = 7 days) * Ciclosporine (wash out period = 14 days) * Azathioprine (wash out period = 14 days) * Mycophenolate mofetil (wash out period = 14 days) * Disulone (wash out period = 7 days) * Corticosteroids (=prednisone, prednisolone, dexamethasone, methylprednisolone) (wash out period = 7 days for doses greater than 5mg) * Patients with contra-indications to treatments : Severe or active infections including tuberculosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite clinico-biological evaluation | 6 months | Response will be assessed at month 6 with a composite endpoint defined as improvement of at least of 2 of the 3 following parameters: * 50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), where clinician will be asked the following question: Please indicate, according to your clinical experience and taking into account all systemic manifestations, the level of disease activity in this patient using the following scale: * and/or 50% improvement of cutaneous activity assessed by the involved skin surface area (according the rule of 9%). Standardised skin pictures will be done in order to centrally review cutaneous response. * and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| liver cell count toxicities | 12 months | to evaluate tolerance |
| kidney cell count toxicities | 12 months | to evaluate tolerance |
| blood cell count toxicities | 12 months | to evaluate tolerance |
| Change in Physician Global Assessment (PGA) | 1 month, | to evaluate clinical efficiency |
| Change in continuous PGA | 9 months | to evaluate clinical efficiency |
| Change in British Isles Lupus Assessment Group (BILAG) | 3 months | to evaluate clinical efficiency |
| Change in Systemic Lupus Erythematosus Responder Index (SRI) | 3 months | to evaluate clinical efficiency |
| Number of Infections | 12 months | to evaluate tolerance |
| Change in 36-Item Short Form Health Survey (SF36) | 3 months | to evaluate clinical efficiency |
| Change in CRP | 1 month | to evaluate biological efficiency |
| Change in ESR (Erythrocyte sedimentation rate) | 1 month | to evaluate biological efficiency |
| Change in Fibrin | 1 month, | to evaluate biological efficiency |
| Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens | 1 month | to evaluate targeted biological efficiency |
| RNA analysis of targeted cytokines and RNA sequencing | 6 months | — |
| Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) | 3 months | to evaluate clinical efficiency |
Countries
France
Contacts
Primary ContactSelim ARACTINGI, PhD
Backup ContactChristelle AUGER
Outcome results
None listed